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We describe our institutional efficacy experience of azithromycin 250 mg thrice weekly in adult
non-cystic fibrosis bronchiectasis.
Methods: Eligibility criteria for prophylactic azithromycin included 3 exacerbations requiring
rescue antibiotics over the previous 6 months. The clinical records of 56 bronchiectasis
patients on azithromycin were retrospectively reviewed. Exacerbation frequency, sputum
microbiology, self-reported change in sputum volume, and spirometry results were recorded.
Results: Mean length of treatment was 9.1 months (7.5) and 50 patients had treatment 3
months. Spirometry, pre- and post-azithromycin in 29 patients, who had 3 or more months
of treatment, showed a mean increase in FEV1 of 83 ml (0.14) (PZ 0.005) from 1.560 to
1.643 l. There was a decrease in the exacerbation frequency from 0.81/month (SD) (0.32)
pre-azithromycin to 0.41/month (0.45) (P< 0.001) post-azithromycin. Clinically significant
suppression of previous sputum microbial isolates was also observed.
Conclusion: Azithromycin improves exacerbation frequency, spirometry, and sputum
microbiology in bronchiectasis.
ª 2008 Published by Elsevier Ltd.44 1912932852; fax: þ44
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8 Published by Elsevier Ltd.Bronchiectasis is a disease characterised by recurrent
bronchial sepsis and exerts considerable morbidity in
many of those affected.1 In the majority of patients treat-
ment is largely confined to ‘‘rescue’’ antibiotics for exacer-
bations. Whilst critical to abrogating individual infections,
this approach has limited effect on chronic symptoms,
exacerbation frequency and possibly disease progression.
Table 1
Pre-AZ Post-AZ
Exacerbation frequency
(SD) per month (nZ 44)
0.81 (0.32) 0.41* (0.45)
FEV1 e litres (nZ 29) 1.560 1.643^
% predicted FEV1 (nZ 29) 57.3% 60.8%^^
Sputum microbiology
(nZ 50; CZ colonized)
No. of positive
sputum cultures
42 13**
Haemophilus influenzae 20 (4C) 4 (1C)
Pseudomonas aeruginosa 16 (9C) 7 (4C)
Streptococcus pneumoniae 10 (2C) 1 (1C)
Moraxella catarrhalis 10 (0C) 0
Staphylococcus aureus 2 (2C) 1 (1C)
Sputum volume daily (nZ 50) All 15 ml 18 (36%
unproductive)
*P< 0.001; ^PZ 0.005; ^^PZ 0.002; **P< 0.005; CZ chronic
colonization, defined as 3 positive cultures of the same
organism at intervals 6 weeks.
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strategy in bronchiectasis but previous studies employing
aminopenicillins and tetracyclines did not reduce exacer-
bation frequency. However, the proven efficacy of
prophylactic macrolide antibiotics in other chronic suppu-
rative conditions, such as diffuse pan-bronchiolitis2 and
cystic fibrosis,3 has led to the frequent ad hoc usage of
macrolides in bronchiectasis with apparent successes in
individual patients. To date, however, there is only a small
body of published evidence to support this strategy.
Tsang et al., in an 8-week placebo-controlled study in 21
patients with idiopathic bronchiectasis, found that low-
dose erythromycin significantly improved lung function and
reduced sputum volume.4 An anecdotal report in 33 bron-
chiectasis patients completing 4 months of azithromycin
therapy suggested a significant reduction in infective exac-
erbations and improvement in symptoms.5 There was also
a significant improvement in carbon monoxide gas transfer
but only a positive trend in spirometric values. The only
randomised study employing azithromycin, to date, in-
volved only 11 patients and utilised an open-label, un-
blinded, 6-month active treatment phase (azithromycin
500 mg twice weekly), and crossover design without pla-
cebo. The exacerbation frequency of the patients prior to
the study was unstated and the majority of patients
received azithromycin in the first 6 months. In the treat-
ment phase there was a significant reduction in exacerba-
tions and sputum volume but there was no change
witnessed in forced expiratory volume in 1 s (FEV1) or
forced expiratory capacity (FVC).6
We, therefore, wished to interrogate the efficacy of
long-term azithromycin 250 mg thrice weekly as prophylac-
tic therapy in patients attending our institutional bronchi-
ectasis clinic from December 2003 to January 2007. The
dose and frequency of azithromycin we employ were
extrapolated from the cystic fibrosis and lung transplanta-
tion literature.7,8 Bronchiectasis was confirmed in all
patients by standard high resolution CT scan criteria.
Patients considered eligible for long-term low-dose azithro-
mycin were those who, despite optimization of standard
care, experienced 3 infective exacerbations in the previ-
ous 6 months. An exacerbation was defined as the presence
of 3 or more of the following symptoms for 24 h: increas-
ing cough; increasing breathlessness and/or wheezing; in-
crease in sputum volume and/or change in sputum colour;
pleuritic chest pain; haemoptysis and/or fever.9 Exclusion
criteria included macrolide allergy and deranged liver func-
tion tests.
In patients on 3 months therapy, the following were
compared:
(1) The number of infective exacerbations 6 months prior
to, and whilst on, treatment (averaged to a monthly
rate).
(2) FEV1 and FVC within 6 months of starting treatment and
most recent on treatment where available. Results
obtained during acute exacerbations were disregarded.
(3) Sputum culture results 12 months prior to, and whilst
on, treatment (chronic colonization defined as 3
positive cultures of the same organism at intervals 6
weeks).
(4) Self-reported sputum volume pre- and post-treatment.Patients who had had a change in other bronchiectasis
treatments within 3 months of commencing azithromycin
(nZ 6) were not included in the exacerbation or lung
function analysis. The data was analysed by paired t-test
and non-parametric Wilcoxin test.
Fifty-six Caucasian patients (18 male/38 female), mean
age 63 12.9 years, were assessed and 22 (39%) had idio-
pathic disease and 34 (61%) had disease of known cause:
post-infectious (nZ 10); COPD (nZ 10); traction (nZ 4);
rheumatoid arthritis (nZ 3); chronic asthma (nZ 3);
allergic bronchopulmonary aspergillosis (nZ 2); hypogam-
maglobulinemia (nZ 1); aspiration (nZ 1).
The mean duration of treatment was 9.1 months (7.5)
with 50 (89%) patients completing 3 months therapy. Six
(11%) patients discontinued treatment due to abdominal
cramps (nZ 2), skin rash (nZ 2) and diarrhoea (nZ 3).
The effects of azithromycin on exacerbation frequency,
FEV1, sputum microbiology and volume are shown in
Table 1. Only 29 (58%) patients were assessable for lung
function analysis due to the stringent criteria outlined
previously.
There was a significant reduction in exacerbation
frequency (P< 0.001) and the number of positive sputum
cultures (P< 0.005) whilst using long-term low-dose
azithromycin. There was a significant improvement in
actual and % predicted FEV1 (1.560 vs 1.643 l, PZ 0.005;
57.3% vs 60.8%, PZ 0.002). There was a non-significant im-
provement in actual and % predicted FVC (2.511 vs 2.60 l,
PZ 0.132; 74% vs 77%, PZ 0.108). FEV1/FVC ratio was
unchanged (0.60 vs 0.61, PZ 0.430).
All 50 patients were producing at least 1 tablespoon (
15 ml) of sputum daily prior to commencing azithromycin
and following treatment 18 patients (36%) became
unproductive.
Our experience supports the previous observations of
Davies et al. that long-term azithromycin appears to
reduce infective exacerbations in bronchiectasis and
supresses airway pathogens, including Pseudomonas
1496 G.A. Anwar et al.aeruginosa (Pa). The mechanism of action of azithromycin
is not fully elucidated but previous studies suggest poten-
tial immunomodulatory, as opposed to anti-microbial ef-
fects. Bronchiectatic airways are characterised by
neutrophilic inflammation and high levels of the pro-in-
flammatory cytokines IL1, IL8 and TNF-a. Erythromycin
significantly reduces the levels of these cytokines in dif-
fuse pan-bronchiolitis2 and in lung transplant patients
with BOS, azithromycin significantly reduces BAL neutro-
philia and IL8 mRNA.10 Azithromycin also has proven pro-
kinetic effects on the gut and treatment in lung allografts
has been associated with lower levels of markers of
aspiration.11
Interestingly, azithromycin has also recently been
shown to improve lung function in patients with BOS,
possibly through inhibition of epithelial cell derived
matrix metalloproteinases12 and this may resonate with
the apparent beneficial effect on FEV1 witnessed in our
patients.
The anti-pseudomonal effect of azithromycin may rep-
resent an inhibitory effect on quorum sensing, biofilm
formation, production of immunostimulatory exoproducts13
and the inflammatory response to this organism.14
We report the efficacy of long-term low-dose azithro-
mycin in bronchiectasis patients with frequent exacerba-
tions. We have demonstrated beneficial effects on
exacerbation frequency, sputum microbiology, FEV1 and
sputum volume and we feel this therapy should be consid-
ered in the chronic management of patients with difficult
to control bronchiectasis.Conflict of interest
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